IP Library Granted Patent US 10,045,981
Granted Patent B2
US 10,045,981 · App. 15/360,198 · Granted Aug 14, 2018

Selective kinase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,045,981
App. No.
15/360,198
Granted
Aug 14, 2018
Kind
B2
Abstract

The present disclosure relates to methods of modulating (for example, inhibiting) activity of JAK3, comprising contacting the JAK3 with a compound of Formula I or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present disclosure further provides novel compounds and compositions as well as their methods of preparation and use. The disclosed JAK3 inhibitors may be used in the treatment of JAK3-associated diseases including, for example, inflammatory and autoimmune disorders.

Claims (16)

1. A JAK3 inhibitor compound selected from:

wherein R 1 is H or C 1 -C 6 alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the JAK3 inhibitor compound is

wherein R 1 is H or C 1 -C 6 alkyl;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the JAK3 inhibitor compound is

wherein R 1 is H or C 1 -C 6 alkyl;

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the JAK3 inhibitor compound is

wherein R 1 is H or C 1 -C 6 alkyl;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the JAK3 inhibitor compound is a compound of formula 1a:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the JAK3 inhibitor compound is a compound of formula 1b:

or a pharmaceutically acceptable salt thereof.

Assignments (4)
SECURITY INTEREST Recorded Mar 15, 2022
From: REACTION BIOLOGY CORPORATION; JAKPHARM, LLC
To: GOLUB CAPITAL LLC, AS COLLATERAL AGENT
Reel/Frame 059267/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2018
From: ACLARIS THERAPEUTICS, INC.
To: JAKPHARM, LLC
Reel/Frame 045872/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2018
From: MA, HAICHING
To: REACTION BIOLOGY CORPORATION
Reel/Frame 045682/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2018
From: REACTION BIOLOGY CORPORATION
To: JAKPHARM, LLC
Reel/Frame 045682/0970 →